The United States filed a complaint under the False Claims Act (FCA) against Regeneron Pharmaceuticals Inc. (Regeneron), a New York-based pharmaceutical company. Regeneron manufactures and sells Eylea, an anti-vascular endothelial growth factor inhibitor approved by the Food and Drug Administration to treat, among other conditions, neovascular Age-Related Macular Degeneration, a prevalent, usually age-related condition that impairs vision. Read More
Home » False Claims Act Complaint Filed Against Regeneron Pharmaceuticals for Fraudulent Drug Pricing Reporting
False Claims Act Complaint Filed Against Regeneron Pharmaceuticals for Fraudulent Drug Pricing Reporting
Related Posts
Armed Drug Cartel Member Sentenced to Over 20 Years in Prison for
A Mexican national and armed member of the Cártel de Jalisco Nueva Generación (CJNG) was sentenced today in the District of Columbia to 20 years… BronArmed Drug Cartel Member Sentenced to Over 20 Years in Prison for
Israeli Freight Forwarder Sentenced to Two Years in Prison for
Gal Haimovich, 49, of Israel, was sentenced today to 24 months in prison and three years of supervised release for conspiracy to illegally ship aircraft… BronIsraeli Freight Forwarder Sentenced to Two Years in Prison for
Saad Healthcare Agrees to Pay $3M to Settle False Claims Act
Saad Enterprises Inc., doing business as Saad Healthcare, has agreed to pay $3 million to resolve allegations that it violated the False Claims Act by… BronSaad Healthcare Agrees to Pay $3M to Settle False Claims Act